Table 1.
Summary of the characteristics of the studies which explored the performance of Quidel Sofia SARS antigen Fluorescent Immunoassay (FIA) for diagnosing acute SARS-CoV-2 infections
| Study | Country | Sample matrix | Sample size | Population | Reference test |
|---|---|---|---|---|---|
| Alonaizan et al., 2022 [16] | Saudi Arabia | Nasal swab | 76 | Asymptomatic | RT-PCR (Cepheid GeneXpert GX-XVI SARS-CoV-2) |
| Alonaizan et al., 2022 [16] | Saudi Arabia | Nasopharyngeal swab | 76 | Asymptomatic | RT-PCR (Cepheid GeneXpert GX-XVI SARS-CoV-2) |
| Bachman et al., 2021 [17] | USA | Nasal swab | 170 | Symptomatic | RT-PCR (CDC 2019-nCoV RT-PCR Diagnostic Panel) |
| Beck et al., 2021 [18] | USA | Nasal swab | 346 | Symptomatic | RT-PCR (Hologic Aptima Panther SARS-CoV-2 TMA test) |
| Bornemann et al., 2022 [19] | Germany | Nasopharyngeal swab | 7859 | Asymptomatic + symptomatic | RT-PCR (Multiple assays) |
| Černila et al., 2023 [20] | Slovenia | Nasopharyngeal swab | 804 | Asymptomatic + symptomatic | RT-PCR (unspecified) |
| Černila et al., 2023 [20] | Slovenia | Nasopharyngeal swab | 132 | Symptomatic | RT-PCR (unspecified) |
| Epling et al., 2022 [21] | USA | Nasal swab | 117 | Symptomatic | RT-PCR (unspecified) |
| Ford et al., 2021 [22] | USA | Nasal swab | 865 | Asymptomatic | RT-PCR (CDC 2019-nCoV RT-PCR Diagnostic Panel) |
| Ford et al., 2021 [22] | USA | Nasal swab | 266 | Symptomatic | RT-PCR (CDC 2019-nCoV RT-PCR Diagnostic Panel) |
| Freeman et al., 2022 [23] | USA | Nasal swab | 138 | Asymptomatic | RT-PCR (Cepheid Xpert Xpress SARS-CoV-2) |
| Freeman et al., 2022 [23] | USA | Nasal swab | 249 | Symptomatic | RT-PCR (Cepheid Xpert Xpress SARS-CoV-2) |
| Hahn et al., 2021 [24] | USA | Nasopharyngeal swab | 60 | Asymptomatic + symptomatic | RT-PCR (New York SARS-CoV-2 RT-PCR) |
| Harmon et al., 2021 [25] | USA | Nasal swab | 23462 | Asymptomatic | RT-PCR (Multiple assays) |
| Harris et al., 2021 [26] | USA | Nasal swab | 885 | Symptomatic | RT-PCR (CDC 2019-nCoV RT-PCR Diagnostic Panel) |
| Jääskeläinen et al., 2021 [27] | Finland | Nasal swab | 148 | Symptomatic | RT-PCR (In-house) |
| Mack et al., 2021 [28] | USA | Nasopharyngeal swab | 10982 | Asymptomatic + symptomatic | RT-PCR (Multiple assays) |
| Mitchell et al., 2021 [29] | USA | Nasal swab | 144 | Asymptomatic | RT-PCR (Cepheid Xpert Xpress SARS-CoV-2) |
| Mitchell et al., 2021 [29] | USA | Nasal swab | 104 | Symptomatic | RT-PCR (Cepheid Xpert Xpress SARS-CoV-2) |
| Porte et al., 2021 [30] | Chile | Nasopharyngeal swab | 64 | Symptomatic | RT-PCR (Primerdesign COVID-19 Genesig) |
| Pray et al., 2021 [31] | USA | Nasal swab | 871 | Asymptomatic | RT-PCR (CDC 2019-nCoV RT-PCR Diagnostic Panel) |
| Pray et al., 2021 [31] | USA | Nasal swab | 53 | Symptomatic | RT-PCR (CDC 2019-nCoV RT-PCR Diagnostic Panel) |
| Smith et al., 2021 [32] | USA | Nasal swab | 43 | Asymptomatic + symptomatic | RT-PCR (Abbott Alinity) |
| Young et al., 2020 [33] | USA | Nasal swab | 251 | Symptomatic | RT-PCR (BD MAX realtime SARS-CoV-2 PCR assay) |